Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?

Nat Rev Cardiol. 2009 Jun;6(6):392-4. doi: 10.1038/nrcardio.2009.60.

Abstract

Proton-pump inhibitors (PPIs) can alter the pharmacodynamic profile of clopidogrel and reduce its platelet-inhibitory effects. Ho and colleagues have reported that concurrent use of PPIs and clopidogrel leads to in an increase in adverse cardiovascular outcomes. In this article we discuss the clinical implications of the interaction between these two drugs.

Publication types

  • News

MeSH terms

  • Acute Coronary Syndrome / blood
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / prevention & control
  • Clopidogrel
  • Drug Interactions
  • Gastrointestinal Hemorrhage / chemically induced
  • Gastrointestinal Hemorrhage / prevention & control
  • Humans
  • Platelet Activation / drug effects*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Proton Pump Inhibitors / therapeutic use*
  • Secondary Prevention
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Proton Pump Inhibitors
  • Clopidogrel
  • Ticlopidine